CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Carbamazepine

· ingredient carbamazepine· CARBAMAZEPINE 100 mg/1; CARBAMAZEPINE 100 mg/5mL; CARBAMAZEPINE 200 mg/1; CARBAMAZEPINE 400 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.23438
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per ML — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other carbamazepine products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.

ProductNADAC / MLvs this
Carbamazepine$0.10059−$0.13380
Carbamazepine$0.12396−$0.11040
Epitol$0.12396−$0.11040
Carbamazepine$0.12396−$0.11040
Carbamazepine$0.12396−$0.11040
Carbamazepine ER$0.49118+$0.25680
Carbamazepin$0.60091+$0.36650
carbamazepine$1.03+$0.79380

Medicare Part D coverage · CY2026

On 214 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 1% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.